Taysha Gene Therapies, Inc. (TSHA)
$4.14-7.80%Close
SELLCRISIS · day 14
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.3B
- Beta
- 1.17
- P/E (TTM)
- -10.39
- Short % float
- 23.35%
- Days to cover
- 11.2
- SI change
- +7.0%
- 1W
- -7.80%
- 1M
- -17.53%
- vs SPY 1W
- -8.22%
- vs SPY 1M
- -19.59%
Industry peers
FMP comparable companies · ranked by market cap
- DNTHSELLDianthus Therapeutics, Inc.$4.9BCRISISQ 2$88.04-0.97%
- ELVNSELLEnliven Therapeutics, Inc.$3.2BCRISISQ 11$45.47-0.34%
- ATAIBUYAtai Beckley Inc.$2.7BBULLQ -2$7.35+0.00%
- XNCRSELLXencor, Inc.$1.9BRECOVERYQ 16$25.63+1.66%
- ANABSELLAnaptysBio, Inc.$1.5BCRISISQ 25$49.20+0.20%
- NKTRSELLNektar Therapeutics$1.2BCRISISQ 12$42.22-3.23%
- IMTXSELLImmatics N.V.$1.0BCRISISQ 6$7.73-2.96%
- SANASELLSana Biotechnology, Inc.$801MCRISISQ -6$2.88-6.09%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on TSHA?
- LOPJLB’s latest quantitative signal on Taysha Gene Therapies, Inc. (TSHA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is TSHA in?
- Taysha Gene Therapies, Inc. (TSHA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Taysha Gene Therapies, Inc. (TSHA) do?
- Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in developme…